ACIU Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

1.22M

+7.71%

-0.156

-2.71%

405.57K

-59.03%

0.000

-100%

45.41M

+3376.69%

0.000

-100%

Estimates Revision

The market is revising No Change the revenue expectations for AC Immune SA (ACIU) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -2.01%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-2.01%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast ACIU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACIU is 10.00 USD with a low forecast of 8.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

8.00

Averages

10.00

High

12.00

Current: 0.000

Low

8.00

Averages

10.00

High

12.00

HC Wainwright & Co.

Andrew Fein

Strong Buy

Reiterates

$16

2025-04-03

Reason

HC Wainwright & Co.

Andrew Fein

Price Target

$16

2025-04-03

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Andrew Fein

Strong Buy

Reiterates

$16

2025-03-14

Reason

HC Wainwright & Co.

Andrew Fein

Price Target

$16

2025-03-14

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for AC Immune SA (ACIU.O) is -6.21, compared to its 5-year average forward P/E of -6.70. For a more detailed relative valuation and DCF analysis to assess AC Immune SA 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.70

Current PE

-6.21

Overvalued PE

3.38

Undervalued PE

-16.79

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-11.30

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

20.64

Undervalued EV/EBITDA

-43.23

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

46.17

Current PS

5.55

Overvalued PS

147.60

Undervalued PS

-55.27

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ACIU News & Events

Events Timeline

No data

News

9.0

2025-12-11Benzinga

AC Immune Study Indicates Promising Early Results for Immunotherapy in Slowing Parkinson's Disease

9.0

2025-12-11Globenewswire

AC Immune's ACI-7104.056 Significantly Slows Parkinson's Disease Progression

9.0

2025-12-11Newsfilter

AC Immune's ACI-7104.056 Shows Significant Slowing of Parkinson's Disease Progression

People Also Watch

Frequently Asked Questions

What is AC Immune SA (ACIU) stock price today?

The current price of ACIU is 3.41 USD — it has decreased -0.87 % in the last trading day.

What is AC Immune SA (ACIU)'s business?

AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.

What is the price predicton of ACIU Stock?

What is AC Immune SA (ACIU)'s revenue for the last quarter?

AC Immune SA revenue for the last quarter amounts to 939.00K USD, decreased -96.32 % YoY.

What is AC Immune SA (ACIU)'s earnings per share (EPS) for the last quarter?

AC Immune SA. EPS for the last quarter amounts to -0.16 USD, decreased -420.00 % YoY.

What changes have occurred in the market's expectations for AC Immune SA (ACIU)'s fundamentals?

How many employees does AC Immune SA (ACIU). have?

AC Immune SA (ACIU) has 133 emplpoyees as of January 10 2026.

What is AC Immune SA (ACIU) market cap?

Today ACIU has the market capitalization of 343.05M USD.